Richard A. Lewis is head of Computer-aided Drug Design at Novartis in Basel with interests in cheminformatics, Machine Learning, protein engineering and structure-based drug design. He earned his B.A. in Natural Sciences (Chemistry) and Ph.D. in pharmacology from Cambridge University, followed by a Fulbright scholarship at UCSF. His career in Pharma began at RPR in 1991 in Computer-Aided Drug Design, moving to Lilly to lead the European CADD team in 1998, before coming to Novartis as head of CADD in 2004. He has authored over 60 papers and patents, and is a fellow of the Royal Society of Chemistry. He is an editor-in-chief of the Journal of Computer-Aided Molecular Design and a member of the Scientific Advisory board of Cresset.